Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now later-stage tilt small index

Dementia, Vascular: later-stage trial registry

3 of 12 indexed Dementia, Vascular trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 3 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Dementia, Vascular: 12 US clinical trials tracked, 3 recruiting.

Dementia, Vascular is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 2 of these trials.

Enrollment posture brief

Registry condition dementia-vascular

OPEN 3 | RECR 25% | LATE 2 | EARLY 0 | RANK #1429 | SPON 2

Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)

Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Dementia, Vascular (this)25%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Dementia, Vascular

Dementia, Vascular lists 3 open slots (25% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Dementia, Vascular on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Dementia, Vascular is recruiting below its size-band peers.

    3 of 12 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Dementia, Vascular research.

    Massachusetts General Hospital accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Typical Dementia, Vascular enrolment sits around 250 participants.

    Median target enrolment is 250 among the 11 trials that report a genuine target (sentinel values excluded). 2 of those (18.2%) plan for fewer than 100 participants.

  4. Dementia, Vascular splits between interventional and observational designs.

    8 interventional and 4 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 31Phase 41

Open and recent trials

12 total, page 1 of 1

RECRUITING 8,000 participants

Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY

Massachusetts General Hospital

NCT04916210

RECRUITING NA 1,800 participants

Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers

University of Washington

NCT05596760

RECRUITING NA 120 participants

Home Tele Rehabilitation Therapy for Vascular Dementia

The Methodist Hospital Research Institute

NCT06289569

ACTIVE NOT RECRUITING 634 participants

Brain Attack Surveillance in Corpus Christi--Cognitive (BASIC-Cognitive)

University of Michigan

NCT03403257

ACTIVE NOT RECRUITING 600 participants

BRINK (BRain In Kidney Disease) Memory Study 2.0

Anne Murray

NCT04975464

ACTIVE NOT RECRUITING NA 250 participants

Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in Stroke Patients Patients

Rush University Medical Center

NCT04337255

COMPLETED NA 418 participants

Rural Dementia Caregiver Project

University of California, San Francisco

NCT04428112

COMPLETED 219 participants

Family Caregiver Online Survey (Dementia and Swallowing Difficulties)

University of Oregon

NCT06471660

COMPLETED NA 182 participants

LEAD IT! An App to Enable Persons With Early Stage Dementia to Lead Group Activities for Their Peers

Hopeful Aging

NCT05516342

COMPLETED NA 20 participants

Zolpidem CR and Hospitalized Patients With Dementia

Massachusetts General Hospital

NCT00814502

COMPLETED Phase 4 11 participants

Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)

VA Office of Research and Development

NCT00385684

COMPLETED Phase 3

Serotonergic Pharmacotherapy for Agitation of Dementia

Bruce Pollock

NCT00009204

Phase Distribution

PhaseTrial count
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Dementia, Vascular records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

placebo with hydrocodone/APAP PRN Drug
1 trials
hydrocodone/APAP Drug
1 trials
hydrocodone/APAP w placebo PRN Drug
1 trials
Building Better Caregivers Workshop Behavioral
1 trials
Perphenazine [Trilafon] Drug
1 trials
Citalopram [Celexa] Drug
1 trials
Zolpidem CR Drug
1 trials
LEAD IT! Programming Behavioral
1 trials

US sites by state

Facility locations filed on Dementia, Vascular trials. A trial with sites in several states counts in each.

Massachusetts 3 trials
Texas 2 trials
Minnesota 2 trials
Illinois 2 trials
California 2 trials
Washington 1 trials
Pennsylvania 1 trials
Oregon 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Dementia, Vascular page

12 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dementia, Vascular condition card totals 12 registered trials; most-linked intervention placebo with hydrocodone/APAP PRN; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.